Consio | $3,300,000 | (Jan 27, 2026)
Orbital(US) | $60,000,000 | (Jan 27, 2026)
Inferact | $150,000,000 | (Jan 27, 2026)
A-Alpha Bio
United States
- Seattle, Washington
- 26/07/2023
- Series A
- $22,400,000
At A-Alpha Bio, we aim to accelerate target discovery, library screening, and preclinical drug characterization by providing cell-based tools for quantitative and high-throughput measurements of protein interactions.
Current approaches for measuring protein interactions are insufficient for many drug development applications due to low accuracy or throughput. We are a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck. AlphaSeq is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. We are seeking industry partnerships to evaluate the use of AlphaSeq for a variety of drug development applications.
A-Alpha Bio, Inc. was founded in 2017 as a spinout from the University of Washington's Institute for Protein Design and Center for Synthetic Biology.
- Industry Biotechnology Research
- Website https://www.aalphabio.com/
- LinkedIn https://www.linkedin.com/company/aalphabio/
Related People
David YoungerCo Founder
United States -
Seattle, Washington
A-Alpha Bio partners with pharmaceutical companies to discover and optimize high-impact therapeutics.
Visitt | $22,000,000 | (Jan 27, 2026)
Cashmere(US) | $5,000,000 | (Jan 27, 2026)
Barnwell Bio | $6,000,000 | (Jan 27, 2026)
Mine(US) | $14,000,000 | (Jan 27, 2026)
Lucend | $3,300,000 | (Jan 27, 2026)
Standard Nuclear | $140,000,000 | (Jan 27, 2026)
Yuki | $6,000,000 | (Jan 23, 2026)
Allocation Strategy | $2,164,392 | (Jan 23, 2026)
Mia Labs | $20,000,000 | (Jan 23, 2026)